Profile data is unavailable for this security.
About the company
KOBAYASHI PHARMACEUTICAL CO., LTD. a drug manufacturer. The Company operates in three segments. The Domestic Household Products Manufacturing and Sales segment and Overseas Household Products Manufacturing and Sales segment offer health care, daily necessities, skin care and other products. The Mail Order segment involves in the mail order of dietary supplements, skin care products and others.
- Revenue in JPY (TTM)176.47bn
- Net income in JPY17.71bn
- Incorporated1919
- Employees3.53k
- LocationKobayashi Pharmaceutical Co LtdKDX Kobayashi Doshomachi Bldg.4-4-10, Dosho-machi, Chuo-kuOSAKA-SHI 541-0045JapanJPN
- Phone+81 662311144
- Websitehttps://www.kobayashi.co.jp/
More ▼
Mergers & acquisitions
| Acquired company | 4967:TYO since announced | Transaction value |
|---|---|---|
| Focus Consumer Healthcare LLC | -16.27% | 75.00m |
Data delayed at least 20 minutes, as of May 24 2024 01:33 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peptidream Inc | 27.97bn | 2.44bn | 242.60bn | 603.00 | 99.01 | 6.05 | 49.53 | 8.67 | 18.85 | 18.85 | 215.77 | 308.51 | 0.4323 | 4.20 | 5.14 | 46,391,190.00 | 3.77 | -- | 4.38 | -- | 59.16 | -- | 8.73 | -- | 3.23 | 2.59 | 0.3505 | -- | 6.93 | -- | -59.81 | -- | -- | -- |
| Nippon Shinyaku Co., Ltd. | 148.25bn | 25.85bn | 249.88bn | 2.19k | 9.27 | 1.09 | 8.09 | 1.69 | 383.80 | 383.80 | 2,201.16 | 3,269.71 | 0.592 | 1.33 | 3.25 | -- | 10.32 | 10.45 | 12.09 | 12.31 | 66.12 | 61.27 | 17.44 | 16.47 | 3.35 | -- | 0.0129 | 32.62 | 2.83 | 5.26 | 13.32 | 9.66 | 45.93 | 12.12 |
| Sawai Group Holdings Co Ltd | 176.86bn | 17.22bn | 259.10bn | 3.39k | 15.09 | 1.22 | 8.43 | 1.46 | 392.06 | 311.79 | 4,029.61 | 4,854.95 | 0.474 | 1.21 | 2.85 | -- | 3.40 | 0.7104 | 4.60 | 0.9705 | 30.71 | 35.08 | 7.17 | 1.47 | 1.50 | 52.16 | 0.2755 | 88.14 | 8.04 | -0.8249 | 46.82 | -2.33 | 18.15 | 0.00 |
| Tsumura & Co | 150.85bn | 16.71bn | 297.67bn | 4.03k | 17.64 | 1.09 | 10.34 | 1.97 | 219.81 | 219.81 | 1,984.75 | 3,566.54 | 0.3657 | 0.748 | 2.42 | -- | 4.37 | 4.81 | 5.43 | 5.89 | 45.62 | 50.98 | 11.96 | 12.65 | 2.39 | -- | 0.2125 | 32.09 | 7.71 | 4.52 | 1.37 | 2.74 | 17.54 | 5.84 |
| Hisamitsu Pharmaceutical Co Inc | 141.71bn | 13.97bn | 315.88bn | 2.77k | 20.50 | 1.06 | 16.11 | 2.23 | 180.93 | 180.93 | 1,840.25 | 3,497.04 | 0.441 | 3.13 | 3.43 | -- | 4.49 | 4.22 | 5.25 | 4.82 | 55.73 | 58.62 | 10.18 | 10.03 | 3.76 | -- | 0.0078 | 52.55 | 10.42 | -0.2385 | 18.97 | -6.17 | 28.90 | 0.5989 |
| Kobayashi Pharmaceutical Co Ltd | 176.47bn | 17.71bn | 436.30bn | 3.53k | 23.91 | 2.03 | 18.06 | 2.47 | 233.81 | 233.81 | 2,340.20 | 2,757.18 | 0.6865 | 3.13 | 4.90 | 49,935,770.00 | 6.89 | 8.01 | 8.53 | 10.18 | 55.53 | 56.45 | 10.03 | 12.24 | 2.19 | -- | 0.0046 | 33.19 | 4.33 | 0.7037 | 1.58 | 2.45 | 29.67 | 8.88 |
| Santen Pharmaceutical Co Ltd | 301.97bn | 26.63bn | 556.19bn | 4.14k | 20.90 | 1.81 | 12.39 | 1.84 | 73.11 | 73.11 | 830.17 | 842.64 | 0.7048 | 2.99 | 3.11 | -- | 6.23 | 3.31 | 7.90 | 4.10 | 59.18 | 59.73 | 8.84 | 5.21 | 2.08 | 5.12 | 0.16 | 81.86 | 8.22 | 5.23 | 278.09 | -3.58 | 5.10 | 4.88 |
| Rohto Pharmaceutical Co Ltd | 270.84bn | 30.94bn | 645.48bn | 7.18k | 20.21 | 2.53 | 19.66 | 2.38 | 135.21 | 135.21 | 1,183.69 | 1,079.72 | 0.8259 | 2.59 | 4.17 | -- | 9.57 | 8.54 | 13.02 | 11.79 | 58.07 | 58.59 | 11.59 | 10.30 | 1.93 | -- | 0.0408 | 19.39 | 13.48 | 8.09 | 17.28 | 25.85 | 5.20 | 18.61 |
Data as of May 24 2024. Currency figures normalised to Kobayashi Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
12.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 09 May 2024 | 2.08m | 2.66% |
| Nomura Asset Management Co., Ltd.as of 30 Apr 2024 | 1.97m | 2.53% |
| Daiwa Asset Management Co. Ltd.as of 30 Apr 2024 | 1.17m | 1.49% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 981.24k | 1.26% |
| Nikko Asset Management Co., Ltd.as of 10 May 2024 | 917.70k | 1.18% |
| Comgest SAas of 30 Jun 2023 | 734.90k | 0.94% |
| BlackRock Fund Advisorsas of 09 May 2024 | 586.70k | 0.75% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 10 May 2024 | 461.80k | 0.59% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 408.15k | 0.52% |
| MFS International Singapore Pte. Ltd.as of 31 Mar 2024 | 348.70k | 0.45% |
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
